NCT00518193

Phase II Study , Association of Cisplatine Topotecan and Cetuximab in Patients Whith Late or in Progress Epithelial Cancer of the Cervix

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 44 (actual)
• Sponsor: ARCAGY/ GINECO GROUP · Academic / Other
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The efficacy of chimiotherapy in cervix epithelial cancer is low even with the association cisplatine - topotecan . News thérapeutics are needed in the goal of increase the survival and quality of life in patients with cervix cancer. Cetuximab has shown the potentialisation on the efficacy of cisplatine and irinotecan. Cisplatine and topotecan have shown an efficacy in cervix cancer. Cetuximab is well tolerate. Many clinical trials shown the faisability of the association of cetuximab and cisplatine in cancer. Many clinical trials have shown the faisability of association of cetuximab and irinotecan in colorectals metastatiques cancers .

Conditions

• Cervix Cancer

Interventions

Type	Name	Description
DRUG	ERBITUX	400 mg/m² 2h injection at week 1, then 250 mg/m² in one hour injection the following weeks

Timeline

• Start date: 2007-04-01
• Primary completion: 2007-07-01
• Completion: 2008-09-01
• First posted: 2007-08-20
• Last updated: 2011-06-30

Locations

4 sites across 1 country: France